Open AccessProtective Effect of Recombinant Human Leukemia Inhibitory Factor against Thrombocytopenia in Carboplatin‐treated Mice
Author(s) -
Akiyama Yasuto,
Kikuchi Yasufumi,
Matsuzaki Junichi,
Kajimura Naoko,
Ohue Chiharu,
Yamaguchi Ken
Publication year - 1997
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1997.tb00422.x
Subject(s) - carboplatin , platelet , medicine , chemotherapy , pharmacology , recombinant dna , leukemia , endocrinology , immunology , cisplatin , biology , biochemistry , gene
The protective effect of recombinant human leukemia inhibitory factor (rhLIF) against development of throrabocytopenia in carboplatin (CBDCA; cis ‐diammine‐l, l‐cyclobutane dicarboxylate platinum II)‐treated mice was examined. The optimal dose of rhLIF was determined by administering doses of rhLIF ranging from 0.2 to 20 μg/day intraperitoneally to normal BALB/c mice, and by analyzing platelet counts. Platelet counts significantly increased at doses over 0.2 μg/day. When 20 μg/day rhLIF was injected for 7 days, platelet counts increased to 240% of control. A remarkable weight loss occurred in the 20μg/day group, but no weight loss was detected at doses of less than 10 μg/day. The rhLIF dose of 4 μg/day was therefore used to examine the protective effect against carboplatin‐induced thrombocytopenia in mice. The intravenous injection of 100 mg/kg carboplatin caused a significant thrombocytopenia with a nadir on day 8. The administration of 4 μg/day rhLIF intraperitoneally for 7 days promoted the recovery of platelet counts from day 5 after the injection of carboplatin. These results suggest that rhLIF at a suboptimal dose might be a useful therapeutic agent for chemotherapy‐induced thrombocytopenia.